Quantitative and Qualitative Analysis of Blood-based Liquid Biopsies to Inform Clinical Decision-making in Prostate Cancer.
Quantitative and Qualitative Analysis of Blood-based Liquid Biopsies to Inform Clinical Decision-making in Prostate Cancer.
复制标题
基于血液的液体活检的定量和定性分析，为前列腺癌的临床决策提供信息。
DOI：
10.1016/j.eururo.2020.12.037
复制
发表时间：
2021-06
期刊：
影响因子：
23.4
通讯作者：
Mateo J
中科院分区：
文献类型：
--
作者：
Casanova-Salas I;Athie A;Boutros PC;Del Re M;Miyamoto DT;Pienta KJ;Posadas EM;Sowalsky AG;Stenzl A;Wyatt AW;Mateo J
基因组分层可以通过有助于临床决策的诊断、预后和预测性生物标志物来影响前列腺癌（PC）治疗。PC的时间和空间基因组异质性以及获取转移性组织活检的挑战阻碍了在常规临床实践中实施基于组织的分子谱分析。基于血液的液体活检是一种有吸引力的微创替代方法。回顾基于血液的液体活检检测在PC中的临床价值，并确定潜在的应用，以加速精准医学的发展。对PubMed/MEDLINE进行了系统性综述，以识别PC中基于血液的循环肿瘤细胞（CTC）、循环肿瘤DNA（ctDNA）和细胞外囊泡（EV）的相关文献。液体活检已经成为一种实用的工具，随着时间的推移，描绘肿瘤动态，阐明随着肿瘤进展而演变的特征（基因组，表观基因组，转录组和蛋白质组）。液体活检测试包括可以在CTC、ctDNA或EV中检测到的DNA、RNA和蛋白质的分析。基于血液的液体活检已证明在局部肿瘤（诊断特征，风险分层和疾病监测）和晚期疾病（反应/耐药生物标志物和预后标志物）的背景下有希望。液体活检具有作为PC预后、预测和反应生物标志物的价值。大多数临床应用已经在晚期转移性环境中开发，其中CTC和ctDNA产量显著更高。然而，在临床实施之前，测定和分析/临床验证的标准化是必要的。可以从前列腺癌患者的血液样品中分离肿瘤的痕量，作为全细胞或DNA片段。这些迹线提供关于肿瘤特征的信息。这些微创检查可以指导诊断和治疗选择。
Genomic stratification can impact prostate cancer (PC) care through diagnostic, prognostic, and predictive biomarkers that aid in clinical decision-making. The temporal and spatial genomic heterogeneity of PC together with the challenges of acquiring metastatic tissue biopsies hinder implementation of tissue-based molecular profiling in routine clinical practice. Blood-based liquid biopsies are an attractive, minimally invasive alternative. To review the clinical value of blood-based liquid biopsy assays in PC and identify potential applications to accelerate the development of precision medicine. A systematic review of PubMed/MEDLINE was performed to identify relevant literature on blood-based circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and extracellular vesicles (EVs) in PC. Liquid biopsy has emerged as a practical tool to profile tumor dynamics over time, elucidating features that evolve (genome, epigenome, transcriptome, and proteome) with tumor progression. Liquid biopsy tests encompass analysis of DNA, RNA, and proteins that can be detected in CTCs, ctDNA, or EVs. Blood-based liquid biopsies have demonstrated promise in the context of localized tumors (diagnostic signatures, risk stratification, and disease monitoring) and advanced disease (response/resistance biomarkers and prognostic markers). Liquid biopsies have value as a source of prognostic, predictive, and response biomarkers in PC. Most clinical applications have been developed in the advanced metastatic setting, where CTC and ctDNA yields are significantly higher. However, standardization of assays and analytical/clinical validation is necessary prior to clinical implementation Traces of tumors can be isolated from blood samples from patients with prostate cancer either as whole cells or as DNA fragments. These traces provide information on tumor features. These minimally invasive tests can guide diagnosis and treatment selection.
登录
查看更多内容
影响因子：
158.5
作者：
Cristofanilli, M;Budd, GT;Hayes, DF
通讯作者：
Hayes, DF
影响因子：
23.4
作者：
De laere, Bram;van Dam, Pieter-Jan;Lindberg, Johan
通讯作者：
Lindberg, Johan
DOI：
10.1158/1078-0432.ccr-15-0137
发表时间：
2016-03-15
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Beltran H;Jendrisak A;Landers M;Mosquera JM;Kossai M;Louw J;Krupa R;Graf RP;Schreiber NA;Nanus DM;Tagawa ST;Marrinucci D;Dittamore R;Scher HI
通讯作者：
Scher HI
影响因子：
4.8
作者：
Donovan, M. J.;Noerholm, M.;Brown, G. A.
通讯作者：
Brown, G. A.
影响因子：
50.3
作者：
Becker A;Thakur BK;Weiss JM;Kim HS;Peinado H;Lyden D
通讯作者：
Lyden D